The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. United Therapeutics Corp shares valued at $2,773,017 were sold by EDGEMOND JAMES on Oct 14 ’24. At $355.88 per share, EDGEMOND JAMES sold 7,792 shares. The insider’s holdings dropped to 5,884 shares worth approximately $2.18 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, JAMES EDGEMOND purchased 7,792 shares, netting a total of over 2,773,017 in proceeds.
Before that, EDGEMOND JAMES had sold 7,794 shares from its account. In a trade valued at $2,771,079, the CFO AND TREASURER traded United Therapeutics Corp shares for $355.54 each. Upon closing the transaction, the insider’s holdings decreased to 7,794 shares, worth approximately $1.98 million.
As published in a research note from Morgan Stanley on July 11, 2024, United Therapeutics Corp [UTHR] has been rated down from an Overweight to an Equal-weight and the price target has been revised to $321 from $310. Analysts at Goldman upgraded the stock from ‘”a Sell”‘ to ‘”a Neutral”‘ outlook in a report released in mid February. As of February 05, 2024, Leerink Partners has initiated its “an Outperform” rating for UTHR. Earlier on December 08, 2023, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for UTHR stock.
Analyzing UTHR Stock Performance
During the last five days, there has been a surge of approximately 3.69%. Over the course of the year, United Therapeutics Corp shares have jumped approximately 68.25%. Shares of the company reached a 52-week high of $374.73 on 10/16/24 and a 52-week low of $208.62 on 02/08/24. A 50-day SMA is recorded $348.23, while a 200-day SMA reached $281.68. Nevertheless, trading volume fell to 0.6 million shares from 0.33 million shares the previous day.
Support And Resistance Levels for United Therapeutics Corp (UTHR)
According to the 24-hour chart, there is a support level at 361.46, which, if violated, would cause prices to drop to 352.95. In the upper region, resistance lies at 376.60. The next price resistance is at 383.23. RSI (Relative Strength Index) is 66.35 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 5.44, which suggests the price will increase in the coming days. Percent R is at 15.14%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
